Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Manuel Ruíz-BorregoAngel Guerrero-ZotanoBegoña BermejoManuel RamosJosefina CruzJose Manuel Baena-CañadaBeatriz CirauquiÁlvaro Rodríguez-LescureEmilio AlbaNoelia Martínez-JáñezMontserrat MuñozSilvia AntolínIsabel ÁlvarezSonia Del BarcoElena SevillanoJosé Ignacio ChacónAntonio AntónMaría José EscuderoVictoria RuizEva CarrascoMiguel Martinnull nullPublished in: Breast cancer research and treatment (2019)
The GEICAM/2006-10 study did not show a statistically significant increase in DFS by adding adjuvant F to A, though no firm conclusions can be drawn because of the limited sample size due to the early stop of the trial. ClinicalTrials.gov: NCT00543127.